Fda expands approval of dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Tarrytown, n.y. and paris, oct. 20, 2021 /prnewswire/ --  dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized phase 3 trial, supporting potential as a best-in-class option only biologic medicine approved for children with oral corticosteroid-dependent asthma regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the u.s. food and drug administration (fda) has approved dupixent® (dupilumab) as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
REGN Ratings Summary
REGN Quant Ranking